NextCure, Inc. (Nasdaq: NXTC) (“NextCure”) and Avere Therapeutics, Inc. (“Avere”), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, announces they have entered into a definitive merger agreement (the “Agreement”) for an all-stock transaction. The Agreement brings together Avere’s differentiated oral IL-23 program with NextCure’s public market infrastructure to accelerate development of AVR-001. Upon completion of the transaction, which is expected to occur in the second half of 2026, the combined company is expected to operate as Avere Therapeutics, Inc., and trade on Nasdaq under the ticker symbol “AVRX.”
Read the full article: NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy //
Source: https://www.globenewswire.com/news-release/2026/07/14/3326655/0/en/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-il-23-therapy.html?_gl=1*qdqjn5*_up*MQ..*_ga*OTA2MjQ4NjEyLjE3ODQwMjgwMDk.*_ga_B6167QB2TF*czE3ODQwMjgwMDgkbzEkZzAkdDE3ODQwMjgwMDgkajYwJGwwJGg3MjU1NTY5Mw..*_ga_ERWPGTJ5X8*czE3ODQwMjgwMDgkbzEkZzAkdDE3ODQwMjgwMDgkajYwJGwwJGgw